WallStSmart

Johnson & Johnson (JNJ)vsViemed Healthcare Inc (VMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 35553% more annual revenue ($96.36B vs $270.28M). JNJ leads profitability with a 21.8% profit margin vs 5.5%. JNJ trades at a lower P/E of 26.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

VMD

Buy

56

out of 100

Grade: C

Growth: 8.7Profit: 5.5Value: 7.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JNJSignificantly Overvalued (-43.5%)

Margin of Safety

-43.5%

Fair Value

$160.13

Current Price

$229.85

$69.72 premium

UndervaluedFair: $160.13Overvalued
VMDUndervalued (+57.1%)

Margin of Safety

+57.1%

Fair Value

$19.68

Current Price

$9.96

$9.72 discount

UndervaluedFair: $19.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$547.28B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
26.4%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
21.8%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

VMD3 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
25.5%8/10

Revenue surging 25.5% year-over-year

EPS GrowthGrowth
29.8%8/10

Earnings expanding 29.8% YoY

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
26.3x4/10

Moderate valuation

PEG RatioValuation
2.962/10

Expensive relative to growth rate

EPS GrowthGrowth
-52.9%2/10

Earnings declined 52.9%

VMD3 concerns · Avg: 3.3/10
P/E RatioValuation
26.7x4/10

Moderate valuation

Market CapQuality
$380.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.

Bull Case : VMD

The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : VMD

The primary concerns for VMD are P/E Ratio, Market Cap, Profit Margin.

Key Dynamics to Monitor

JNJ profiles as a mature stock while VMD is a growth play — different risk/reward profiles.

VMD carries more volatility with a beta of 1.16 — expect wider price swings.

VMD is growing revenue faster at 25.5% — sustainability is the question.

JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (59/100 vs 56/100), backed by strong 21.8% margins. VMD offers better value entry with a 57.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Viemed Healthcare Inc

HEALTHCARE · MEDICAL DEVICES · USA

Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.

Want to dig deeper into these stocks?